June 18, 2018:
FORGE Life Science enters into a Cooperative Research & Development Agreement with the U.S. Army Medical Research Institute of Infectious Disease to test FORGE host-targeted antivirals against Department of Defense priority pathogens such as Marburg virus, Venezuelan equine encephalitis virus, and Lassa virus.